This finding may have important implications for clinical practice, as the levels of RNF144B could serve as a prognostic marker and potentially identify patients who will not benefit from DNA damage or CIN-inducing therapies, specifically in Tp53 wild-type LUAD cancers. The gene discussed is TP53; the disease is cervical squamous intraepithelial neoplasia.